José-Tomás Navarro

Prof. José-Tomás Navarro

1. Lymphoid Neoplasms Group, Josep Carreras Leukaemia Research Institute, Can Ruti Campus, 08916 Badalona, Spain
+2
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2013 in Blood
Verified
Journal Article
Closed access
PDF file
SBStefan K Barta
Stefan K Barta
XXXiaonan Xue
Xiaonan Xue
DWDan Wang
Dan Wang
RTRoni Tamari
Roni Tamari
JLJeannette Y. Lee
Jeannette Y. Lee
JSJoseph A. Sparano
Joseph A. Sparano
Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P < .001), improved PFS (hazard ratio [HR] 0.50; P < .001), and OS (HR 0.51; P < .0001). Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted in better CR rates (ACVBP [doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P < .04), PFS (ACVBP: HR 0.72; P = .049; “intensive regimens”: HR 0.35; P < .001) and OS (“intensive regimens”: HR 0.54; P < .001). Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamide (EPOCH) was associated with significantly better OS in diffuse large B-cell lymphoma (HR 0.33; P = .03). Concurrent use of cART was associated with improved CR rates (OR 1.89; P = .005) and trended toward improved OS (HR 0.78; P = .07). These findings provide supporting evidence for current patterns of care where definitive evidence is unavailable. Key Points Rituximab use is associated with significant improvement in all outcomes for patients with HIV-associated CD20-positive lymphomas. Infusional EPOCH chemotherapy is associated with better overall survival in patients with AIDS-related diffuse large B-cell lymphoma (DLBCL).

17 April 2012 in Cancer
Verified
Journal Article
Closed access
PDF file
JCJorge J Castillo
Jorge J Castillo
MFMichael Furman
Michael Furman
BBBrady E. Beltrán
Brady E. Beltrán
MBMichele Bibas
Michele Bibas
PBProfessor Mark Bower
Professor Mark Bower
JVJulie M. Vose
Julie M. Vose

1 February 2007 in Haematologica
Verified
Journal Article
Closed access
PDF file
BXBlanca Xicoy
Blanca Xicoy
JRJose-Maria Ribera
Jose-Maria Ribera
PMP. Miralles
P. Miralles
JBJ. Berenguer
J. Berenguer
RRR. Rubio
R. Rubio
SGSpain Gesida Gelcab Groups
Spain Gesida Gelcab Groups
Background and Objectives Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin’s lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce. We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL. Design and Methods From January 1996 to December 2005, 62 HIV-infected patients with newly diagnosed HL were treated in 15 Spanish hospitals. Six to eight cycles of ABVD and HAART were planned. Response to chemotherapy, overall survival (OS) and event-free survival (EFS) were recorded. Results The median age of the patients was 37 years (range, 24–61) and 29 (47%) had a previously known diagnosis of acquired immunodeficiency syndrome. The median CD4 lymphocyte count at diagnosis was 129/μL (range 5–1,209). The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and non-specified in the remaining 10 (16%). Twenty-one (34%) patients were in stage III and 41 (66%) in stage IV. The scheduled six to eight ABVD cycles were completed in 82% of cases. Six patients died during induction, 54 (87%) achieved a complete response (CR) and two were resistant. After a median follow-up of 39 and 47 months, 5-year EFS and OS probabilities were 71% (47–95) and 76% (65–87), respectively. An immunological response was observed in 24 out of 43 patients (56%) and a virological response in 27 out of 40 (68%). The immunological response to HAART had a positive impact on OS and EFS (p=0.002 and p=0.001, respectively). Interpretation and Conclusions In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective. This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly. An immunological response to HAART has a positive impact on OS and EFS.

12 March 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JCJorge J Castillo
Jorge J Castillo
TGThomas Guerrero‐Garcia
Thomas Guerrero‐Garcia
FBFrancesco Baldini
Francesco Baldini
ETEmmanuelle Tchernonog
Emmanuelle Tchernonog
GCGuillaume Cartron
Guillaume Cartron
MBMichele Bibas
Michele Bibas
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.


20 October 2011 in Histopathology
Verified
Journal Article
Closed access
PDF file
GTGustavo Tapia
Gustavo Tapia
RLRaquel Lopez
Raquel Lopez
AMAna María Muñoz-Mármol
Ana María Muñoz-Mármol
JMJosé L Mate
José L Mate
CSCarolina Sanz
Carolina Sanz
AAAurelio Ariza
Aurelio Ariza